AGA guidelines recommend testing for Lynch syndrome in all patients with colorectal cancer
the ONA take:
The American Gastroenterological Association has published a new guideline for colorectal cancer (CRC). The guideline, published in Gastroenterology, recommends all patients with a new diagnosis of CRC should undergo testing for Lynch syndrome.
Lynch syndrome is an inherited disorder in which the MMR gene is mutated, making the body less able to fix errors in the DNA. The syndrome is the most common inherited cause of colorectal cancer, affecting approximately 700,000 Americans. Children have an approximately 50% chance of inheriting the disorder. Most people with the syndrome are not aware that they have it.
Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 30% of persons who develop CRC have a family history of the disease, and 5% to 6% have mutations diagnostic of a known hereditary cancer syndrome. Persons with Lynch syndrome have an 80% higher risk for colorectal cancer and a 60% higher risk for endometrial cancer.
AGA recommends all patients with colorectal cancer get tested for Lynch syndrome
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
- Sexual Aids and Resources Not Readily Available at Cancer Centers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|